Listen "Analyzing Johnson & Johnson's Steady Growth, Dividend, and Analyst Outlook"
Episode Synopsis
As of the latest update, Johnson and Johnson's stock price is around one hundred sixty-two dollars and twelve cents per share. The trading volume has been notably lower than average, with recent days seeing a significant decline compared to the usual daily volume. For instance, on a recent trading day, the volume was eighty-two percent below the average daily volume of approximately seven million, three hundred thirty-two thousand shares.Recently, Johnson and Johnson reported strong fourth-quarter results for two thousand twenty-four, with a five-point-three percent increase in sales. The company's MedTech segment showed significant growth, driven by electrophysiology products and wound closure solutions. For the full year two thousand twenty-five, Johnson and Johnson expects operational sales to grow between two-point-five and three-point-five percent.In terms of analyst updates, several firms have adjusted their price targets for Johnson and Johnson. Bank of America raised its target from one hundred fifty-nine dollars to one hundred seventy-one dollars, while Royal Bank of Canada maintained an outperform rating with a target of one hundred eighty-one dollars. Citigroup reduced its target from one hundred eighty-five dollars to one hundred seventy-five dollars but maintained a buy rating. Overall, the consensus among analysts is a moderate buy with a target price of approximately one hundred seventy-one dollars and thirty-three cents.Johnson and Johnson also recently announced a quarterly dividend of one dollar and twenty-four cents per share, reflecting a yield of approximately three-point-zero-four percent. The company's financial health and consistent dividend payouts make it an attractive option for investors seeking stability. Despite the recent low trading volume, Johnson and Johnson remains a significant player in the healthcare sector, with a market capitalization of nearly three hundred ninety-four billion dollars.For more http://www.quietplease.aiStock up on these deals https://amzn.to/3QFpYIXThis content was created in partnership and with the help of Artificial Intelligence AI
More episodes of the podcast Johnson & Johnson News Daily
Johnson & Johnson Stock Update: Moderate Buy Consensus, Strong Fundamentals Ahead of Q4 Earnings
02/01/2026
Johnson & Johnson Stock Update December 2025: Steady Blue-Chip Performance, Analyst Optimism
26/12/2025
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.